Cvs: Drugstore Cowboy

How long can the chain keep its galloping expansion going?

Is CVS Corp. taking growth hormones? On Feb. 9, the drug chain announced it would acquire Detroit-based Arbor Drugs Inc. in a $1.48 billion stock deal. The next day, New York rival Duane Reade got caught in the CVS whirlwind: On the first day of public trading, Duane Reade's shares closed 31% above their IPO pricing, partly on speculation that the chain might be CVS' next target.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.